AU2009246683A1

AU2009246683A1 - Anti-CXCR4 antibodies

Info

Publication number: AU2009246683A1
Application number: AU2009246683A
Authority: AU
Inventors: Cindy Takeuchi Dickerson; David Matthew Marquis; Victor Obungu; Sheng-Bin Peng; Peter Edward Vaillancourt
Original assignee: Eli Lilly and Co
Current assignee: Eli Lilly and Co
Priority date: 2008-05-14
Filing date: 2009-05-07
Publication date: 2009-11-19
Also published as: EA201071300A1; IL208869A0; MX2010012435A; KR20100133012A; CN102027015A; CA2724409A1; EP2297206A1; WO2009140124A1; JP2011520885A; ZA201007955B

Description

WO 2009/140124 PCT/US2009/043063 ANTI-CXCR4 ANTIBODIES The present invention relates to monoclonal antibodies against CXCR4 and their use in treating diseases in which pathogenesis is mediated by CXCR4 and SDF-1. CXCR4, a chemokine receptor, is a G protein-coupled, seven-transmembrane 5 receptor. Like other chemokine receptors, CXCR4 plays an important role in immune and inflammatory responses by mediating the directional migration and activation of leukocytes. CXCR4 is expressed or overexpressed in a variety of cancer cell lines and tissues including breast, prostate, lung, ovarian, colon, pancreatic, kidney, and brain, as well as non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The only known 10 ligand to CXCR4 is stromal cell-derived factor-i (SDF-1, or CXCL12). The CXCR4 and SDF-1 interaction plays an important role in multiple phases of tumorigenesis, including tumor growth, invasion, angiogenesis, and metastasis. In view of the involvement of CXCR4 in various serious diseases, CXCR4 has been studied as a therapeutic target. For example, AMD3 100, a bicyclam CXCR4 15 antagonist, is available for patients with multiple myeloma and non-Hodgkins lymphoma. CTCE9908, a peptide CXCR4 antagonist, is currently in Phase lb/II clinical trials for cancer. In addition, antibodies targeting CXCR4 are disclosed in the art (WO 06/089141, US 07/0059308, and in Carnec et al [Carnec X, Quan L, Olson W, Hazan U, Dragic T. (2005) Anti-CXCR4 Monoclonal Antibodies Recognizing Overlapping Epitopes Differ 20 Significantly in Their Ability To Inhibit Entry of Human Immunodeficiency Virus Type I. Journal of Virology. Feb.2005: 1930-1933]). Although there are various agents under development that target CXCR4, there still exists a need for additional therapeutic agents targeting CXCR4. The antibodies of the present invention are therapeutically useful CXCR4 antagonists possessing a number 25 of desirable properties. Antibodies of the present invention have increased chemical and physical stability, and solubility. The present invention provides CXCR4 antibodies that bind human CXCR4 with high affinity and inhibit human CXCR4 binding to SDF- 1. High potency permits the use of low doses in therapeutic regimens. In addition, these antibodies interfere with the interaction of SDF- 1 to CXCR4, and thus reduce 30 tumorigenesis, including tumor growth, invasion, angiogenesis, and metastasis. Furthermore, antibodies of the present invention induce apoptosis of tumor cells.

WO 2009/140124 PCT/US2009/043063 -2 The present invention includes a human engineered antibody or a binding fragment thereof, that binds human CXCR4, and which: a. inhibits binding of human SDF-la (SEQ ID NO:33) to CXCR4 with an

IC

50 for human CXCR4 between 10 nM and 0.05 nM in a human 5 CXCR4/ 125 I-SDF-1a binding inhibition assay as described herein; b. inhibits migration of cells bearing CXCR4 on their surface with an IC 50 between 30 nM and 0.3 nM in the chemotaxis assay as described herein; and c. exhibits an affinity, KD between 15 nM and 0.05 nM in the Surface 10 Plasmon Reasonance (BlAcore) assay as described herein. The present invention preferably provides a human engineered antibody or a binding fragment thereof, that binds human CXCR4, and which inhibits binding of human SDF-Ia (SEQ ID NO:33) to CXCR4 with an IC 50 for human CXCR4 between 0.5 nM and 0.05 nM in a human CXCR4/ 125 I-SDF-la binding inhibition assay as described 15 herein. The present invention preferably provides a human engineered antibody or a binding fragment thereof, that binds human CXCR4, and which inhibits migration of cells bearing CXCR4 on their surface with an IC 50 between 3.0 nM and 0.3 nM in the chemotaxis assay as described herein. 20 The present invention preferably provides a human engineered antibody or a binding fragment thereof, that binds human CXCR4, and which exhibits an affinity, KD between 1.0 nM and 0.05 nM in the Surface Plasmon Reasonance (BlAcore) assay as described herein. The present invention preferably provides a human engineered antibody or a 25 binding fragment thereof, that binds human CXCR4, and which exhibits anti tumorigenesis activity by preventing tumor growth in a tumor xenograft model as described herein when administered at 1 mg/kg. The present invention preferably provides a human engineered antibody or a binding fragment thereof, that binds human CXCR4, and which induces apoptosis of 30 tumor cells in an apoptosis assay as described herein when administered between 2 pg/mL and 10 pg/mL.

WO 2009/140124 PCT/US2009/043063 -3 The present invention includes a human engineered antibody or a binding fragment thereof, that comprises a light chain comprising a light chain variable region that comprises framework regions, CDRL 1 having the amino acid sequence of SEQ ID NO:8, CDRL2 having the amino acid sequence of SEQ ID NO:9, and CDRL3 having the 5 amino acid sequence of SEQ ID NO: 10, and a heavy chain comprising a heavy chain variable region that comprises framework regions, CDRH 1 having the amino acid sequence of SEQ ID NO: 1, CDRH3 having the amino acid sequence of SEQ ID NO:3, and CDRH2 having an amino sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, wherein the 10 antibody binds to human CXCR4. Further, the present invention includes an antibody that binds human CXCR4, wherein a light chain comprises an amino acid sequence of SEQ ID NO: 16, and a heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:15. 15 In addition, the present invention includes an antibody that binds human CXCR4, wherein a light chain comprises an amino acid sequence of SEQ ID NO:22, and a heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, and SEQ ID NO:21. The present invention also includes an antibody that binds human CXCR4, 20 wherein an antibody is selected from the group consisting of an antibody comprising SEQ ID NO:17 and SEQ ID NO:22, an antibody comprising SEQ ID NO:18 and SEQ ID NO:22, an antibody comprising SEQ ID NO:19 and SEQ ID NO:22, an antibody comprising SEQ ID NO:20 and SEQ ID NO:22, and an antibody comprising SEQ ID NO:21 and SEQ ID NO:22. 25 The antibodies of the present invention as defined herein are characterized by having an IC 5 o of 10 nM or less in a human CXCR4/ 12 5 I-SDF-Ia binding inhibition assay as described herein. Preferred antibodies of the invention have a binding affinity for human CXCR4 of 5.0 nM or less. Most preferred antibodies of the invention have a binding affinity for human CXCR4 of 0.5 nM or less. Further preferred, antibodies of the 30 present invention have an IC 50 for human CXCR4 between 10 nM and 0.05 nM in a human CXCR4/ 12 5 I-SDF-la binding inhibition assay as described herein. Further preferred, antibodies of the present invention have an IC 50 for human CXCR4 between WO 2009/140124 PCT/US2009/043063 -4 0.5 nM and 0.05 nM in a human CXCR4/ 125 1-SDF-1a binding inhibition assay as described herein. The antibodies of the present invention as defined herein are characterized by having an IC 50 of 30 nM or less in a chemotaxis assay as described herein. Preferred 5 antibodies of the invention have an IC 50 of 15 nM or less in the chemotaxis assay. More preferred antibodies of the invention have an IC 50 of 3.0 nM or less in the chemotaxis assay. Further preferred, antibodies of the present invention have an IC 50 between 30 nM and 0.3 nM in the chemotaxis assay as described herein. Further preferred, antibodies of the present invention have an IC 50 between 3.0 nM and 0.3 nM in the chemotaxis assay as 10 described herein. The antibodies of the present invention as defined herein are characterized by having a KD of 15 nM or less in an assay that evaluates the binding activities of the antibodies by Surface Plasmon Reasonance (BlAcore) as described herein. More preferred antibodies of the invention KD of 10 nM or less in the BlAcore assay. Most 15 preferred antibodies of the invention have KD of 1.0 nM or less in the BlAcore assay. Further preferred, antibodies of the present invention have KD between 15 nM and 0.05 nM in the BlAcore assay as described herein. Further preferred, antibodies of the present invention have KD between 1.0 nM and 0.05 nM in the BlAcore assay as described herein. 20 The antibodies of the present invention as defined herein are characterized by having anti-tumorigenesis activity by preventing tumor growth in a tumor xenograft model using NOD/SCID mice and human non-Hodgkin's lymphoma Namalwa cells as described herein when administered at 10 mg/kg. More preferred antibodies of the invention have having anti-tumorigenesis activity by preventing tumor growth when 25 administered at 1 mg/kg. The antibodies of the present invention as defined herein are characterized by inducing apoptosis of tumor cells in an apoptosis assay as described herein. More preferred antibodies of the invention induce nuclear fragmentation and activation of caspase 3, hallmarks of apoptosis, in multiple tumor cells including Namalwa and CEM 30 cells when administered between 2 pg/mL and 10 pg/mL. The present invention includes a pharmaceutical composition comprising an antibody as described herein in combination with one or more pharmaceutically WO 2009/140124 PCT/US2009/043063 -5 acceptable carriers, diluents, or excipients. In addition, the present invention includes a pharmaceutical composition for the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis, comprising an antibody as variously described herein, in combination with one or more pharmaceutically acceptable carriers, diluents, or 5 excipients. Further, the present invention includes a pharmaceutical composition for the treatment of a cancer selected from the group consisting of breast cancer, pancreatic cancer, melanoma, prostate cancer, kidney cancer, neuroblastoma, non-Hodgkin's lymphoma, lung cancer, ovarian cancer, colorectal cancer, multiple myeloma, glioblastoma multiforme, and leukemia comprising an antibody as variously described 10 herein, in combination with one or more pharmaceutically acceptable carriers, diluents, or excipients. The present invention includes the use of an antibody as described herein for the preparation of a medicament for the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis. In addition, the present invention includes the use 15 of an antibody as described herein for the preparation of a medicament for the treatment of a cancer selected from the group consisting of breast cancer, pancreatic cancer, melanoma, prostate cancer, kidney cancer, neuroblastoma, non-Hodgkin's lymphoma, lung cancer, ovarian cancer, colorectal cancer, multiple myeloma, glioblastoma multiforme, and leukemia. 20 The present invention includes a method of treating tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis, comprising administering to a patient in need of an antibody as described herein. Further, the present invention includes a method of treating a cancer selected from the group consisting of breast cancer, pancreatic cancer, melanoma, prostate cancer, kidney cancer, neuroblastoma, non 25 Hodgkin's lymphoma, lung cancer, ovarian cancer, colorectal cancer, multiple myeloma, glioblastoma multiforme, and leukemia, comprising administering to a patient in need of an antibody as described herein. The general structure of an "antibody," is very well-known in the art. For an antibody of the IgG type, there are four amino acid chains (two "heavy" chains and two 30 "light" chains) that are cross-linked via intra- and inter-chain disulfide bonds. When expressed in certain biological systems, antibodies having unmodified human Fc sequences are glycosylated in the Fc region. Antibodies may be glycosylated at other WO 2009/140124 PCT/US2009/043063 -6 positions as well. The subunit structures and three-dimensional configurations of antibodies are well known in the art. Each heavy chain is comprised of an N-terminal heavy chain variable region ("HCVR") and a heavy chain constant region ("HCCR"). The heavy chain constant region is comprised of three domains (CHI, CH2, and CH3) for 5 IgG, IgD, and IgA; and 4 domains (CHI, CH2, CH3, and CH4) for IgM and IgE. Each light chain is comprised of a light chain variable region (herein "LCVR") and a light chain constant region ("LCCR"). The variable regions of each light/heavy chain pair form the antibody binding site. The HCVR and LCVR regions can be further subdivided into regions of hypervariability, 10 termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FR). Each HCVR and LCVR are composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FRI, CDR1, FR2, CDR2, FR3, CDR3, FR4. Herein, the 3 CDRs of the heavy chain are referred to as "CDRH1, CDRH2, and CDRH3" and the 3 CDRs of the 15 light chain are referred to as "CDRL1, CDRL2 and CDRL3." The CDRs contain most of the residues which form specific interactions with the antigen. The assignment of amino acids to each domain is in accordance with well-known conventions [e.g., Kabat, "Sequences of Proteins of Immunological Interest," National Institutes of Health, Bethesda, Md. (1991)]. 20 Antibodies of the present invention may have a heavy chain constant region selected from any of the immunoglobulin classes (IgA, IgD, IgG, IgM, and IgE). Furthermore, antibodies of the present invention contain an Fc portion which is derived from human IgG4 Fc region because of its reduced ability to bind complement factors as compared to other IgG sub-types. 25 An antibody may be derived from a single copy or clone, including e.g., any eukaryotic, prokaryotic, or phage clone. Preferably an antibody of the invention exists in a homogeneous or substantially homogeneous population. An antibody can be intact, comprising complete or full length constant regions, including the Fc region, or a portion or fragment of such an antibody provided that any shortened form comprises the antigen 30 binding portion and retains antigen-binding capability. Such shortened forms include, e.g., a Fab fragment, Fab' fragment or F(ab') 2 fragment that includes the CDRs or the variable regions of the anti-CXCR4 antibodies disclosed. Furthermore, such shortened WO 2009/140124 PCT/US2009/043063 -7 antibody forms can be a single chain Fv fragment that may be produced by joining the DNA encoding the LCVR and HCVR with a linker sequence. (See, Pluckthun, The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer Verlag, New York, pp 269-315, 1994). Regardless of whether fragments or portions are 5 specified, the term "antibody" as used herein includes such fragments or portions as well as single chain forms unless otherwise indicated. As long as the protein retains the ability to specifically or preferentially bind CXCR4 and includes a sequence or sequences disclosed herein, it is included within the term "antibody." Antibodies of the invention can be produced using techniques well known in the art, e.g., recombinant technologies, 10 phage display technologies, synthetic technologies or combinations of such technologies or other technologies readily known in the art. The term "human engineered antibody" refers to an antibody having frameworks, hinge regions, and constant regions of human origin that are identical with or substantially identical (substantially human) with frameworks and constant regions 15 derived from human genomic sequences. Fully human frameworks, hinge regions, and constant regions are those human germline sequences as well as sequences with naturally occurring somatic mutations. A human engineered antibody may comprise framework, hinge, or constant regions derived from a fully human framework, hinge, or constant region containing one or more amino acid substitutions, deletions, or additions therein. 20 Often, a human engineered antibody is preferably substantially non-immunogenic in humans. A variety of different human framework sequences may be used singly or in combination as a basis for the human engineered antibodies of the present invention. Preferably, the framework regions of the antibodies of the invention are of human origin 25 or substantially human (at least 95%, 97% or 99% of human origin.) The sequences of framework regions of human origin may be obtained from The Immunoglobulin Factsbook, by Marie-Paule Lafranc, Gerard Lefranc, Academic Press 2001, ISBN 012441351. The framework sequence for the human engineered antibodies of the present 30 invention serves as the "donor" variable framework region and can be used to create additional human engineered antibodies with the same CDRs specified herein using methodology known in the art. Furthermore, the framework sequence for the human WO 2009/140124 PCT/US2009/043063 -8 engineered antibodies of the present invention can be compared to other known human framework sequences to generate additional human engineered antibodies. Thus, this information can be used to "back-mutate" another selected homologous human framework region to the human engineered donor amino acid residue at these positions. 5 Further, any "rare" amino acids can be detected in additional human frameworks such that the concensus or donor human engineered amino acid residue can be used at the relevant position. The term "inhibit" means the ability to substantially antagonize, prohibit, prevent, restrain, slow, disrupt, eliminate, stop, reduce or reverse the biological effects of binding 10 to the CXCR4 receptor. "CXCR4" or "human CXCR4" refers to any human CXCR4, as well as functionally active, mutated forms thereof. Examples include, but are not limited to, SEQ ID NO:30, SEQ ID NO:31, and SEQ ID NO:32. A "patient" is a mammal, preferably a human. 15 The term "treating" (or "treat" or "treatment") means slowing, stopping, reducing, or reversing the progression or severity of a symptom, disorder, condition, or disease. The term "preventing" (or "prevent" or "prevention") means prohibiting, restraining, or inhibiting the incidence or occurrence of a symptom, disorder, condition, or disease. Acute events and chronic conditions may be treated and prevented. In an 20 acute event, antibody is administered at the onset of a symptom, disorder, condition, or disease and discontinued when the acute event ends, whereas a chronic symptom, disorder, condition, or disease is treated over a more protracted time frame. The term "therapeutically effective amount" refers to the amount or dose of an antibody of this invention which, upon single or multiple dose administration to a patient, 25 provides the desired treatment or prevention. The therapeutically effective amount can comprise an amount of about 0.00 1 to 20 mg/kg per single (e.g., bolus), multiple or continuous administration. Particular antibodies of this invention include: an antibody comprising amino acid sequences of SEQ ID NOs: 1, 2, 3, 8, 9, and 10; an antibody comprising amino acid 30 sequences of SEQ ID NOs: 1, 4, 3, 8, 9, and 10; an antibody comprising amino acid sequences of SEQ ID NOs: 1, 5, 3, 8, 9, and 10; an antibody comprising amino acid sequences of SEQ ID NOs: 1, 6, 3, 8, 9, and 10; an antibody comprising amino acid WO 2009/140124 PCT/US2009/043063 -9 sequences of SEQ ID NOs: 1, 7, 3, 8, 9, and 10. The listed sequences represent CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3, respectively. Particular antibodies of this invention include: an antibody comprising a LCVR having an amino acid sequence of SEQ ID NO: 16 and a HCVR having an amino acid 5 sequence of SEQ ID NO: 11; an antibody comprising a LCVR having an amino acid sequence of SEQ ID NO: 16 and a HCVR having an amino acid sequence of SEQ ID NO: 12; an antibody comprising a LCVR having an amino acid sequence of SEQ ID NO: 16 and a HCVR having an amino acid sequence of SEQ ID NO:13; an antibody comprising a LCVR having an amino acid sequence of SEQ ID NO: 16 and a HCVR 10 having an amino acid sequence of SEQ ID NO: 14; an antibody comprising a LCVR having an amino acid sequence of SEQ ID NO: 16 and a HCVR having an amino acid sequence of SEQ ID NO:15. The present invention includes five antibodies that bind and inhibit CXCR4 activity. In particular, the present invention includes: an antibody comprising a light 15 chain having an amino acid sequence of SEQ ID NO: 22 and a heavy chain having an amino acid sequence of SEQ ID NO: 17; an antibody comprising a light chain having an amino acid sequence of SEQ ID NO: 22 and a heavy chain having an amino acid sequence of SEQ ID NO: 18; an antibody comprising a light chain having an amino acid sequence of SEQ ID NO: 22 and a heavy chain having an amino acid sequence of SEQ 20 ID NO: 19; an antibody comprising a light chain having an amino acid sequence of SEQ ID NO: 22 and a heavy chain having an amino acid sequence of SEQ ID NO: 20; an antibody comprising a light chain having an amino acid sequence of SEQ ID NO: 22 and a heavy chain having an amino acid sequence of SEQ ID NO: 21. Preferably, an antibody of the present invention wherein all six CDRs, the HCVR, 25 the LCVR, the HCVR and the LCVR, the entire heavy chain, the entire light chain, or the entire heavy chain and light chain are limited by a particular sequence as shown by a SEQ ID NO: herein is further characterized by having an IC 5 o in a human CXCR4/ 125 I-SDF-la binding inhibition assay as described herein of about of 10 nM or less, more preferably about 5.0 nM or less, and most preferably of 0.5 nM or less. Further preferred, an 30 antibody of the present invention wherein all six CDRs, the HCVR, the LCVR, the HCVR and the LCVR, the entire heavy chain, the entire light chain, or the entire heavy chain and light chain are limited by a particular sequence as shown by a SEQ ID NO: WO 2009/140124 PCT/US2009/043063 -10 herein is further characterized by having an IC 50 for human CXCR4 between 10 nM and 0.05 nM in a human CXCR4/ 125 1-SDF-la binding inhibition assay as described herein. Further preferred, an antibody of the present invention wherein all six CDRs, the HCVR, the LCVR, the HCVR and the LCVR, the entire heavy chain, the entire light chain, or the 5 entire heavy chain and light chain are limited by a particular sequence as shown by a SEQ ID NO: herein is further characterized by having an IC 50 for human CXCR4 between 0.5 nM and 0.05 nM in a human CXCR4/ 125 1-SDF-1a binding inhibition assay as described herein. More preferably, an antibody of the present invention wherein all six CDRs, the 10 HCVR, the LCVR, the HCVR and the LCVR, the entire heavy chain, the entire light chain, or the entire heavy chain and light chain are limited by a particular sequence as shown by a SEQ ID NO: herein is further characterized by having an IC 50 in a chemotaxis assay as described herein of about 30 nM or less, more preferably about 15 nM or less, and even more preferably 3.0 nM or less. Further preferred, an antibody of the present 15 invention wherein all six CDRs, the HCVR, the LCVR, the HCVR and the LCVR, the entire heavy chain, the entire light chain, or the entire heavy chain and light chain are limited by a particular sequence as shown by a SEQ ID NO: herein is further characterized by having an IC 50 between 30 nM and 0.3 nM in the chemotaxis assay as described herein. Further preferred, an antibody of the present invention wherein all six 20 CDRs, the HCVR, the LCVR, the HCVR and the LCVR, the entire heavy chain, the entire light chain, or the entire heavy chain and light chain are limited by a particular sequence as shown by a SEQ ID NO: herein is further characterized by having an IC 50 between 3.0 nM and 0.3 nM in the chemotaxis assay as described herein. Even more preferably, an antibody of the present invention wherein all six CDRs, 25 the HCVR, the LCVR, the HCVR and the LCVR, the entire heavy chain, the entire light chain, or the entire heavy chain and light chain are limited by a particular sequence as shown by a SEQ ID NO: herein is further characterized by having a KD in an assay that evaluates the binding activities of the antibodies by Surface Plasmon Reasonance (BlAcore) as described herein of about 15 nM or less, more preferably about 10 nM or 30 less, and most preferably 1.0 nM or less. Further preferred, an antibody of the present invention wherein all six CDRs, the HCVR, the LCVR, the HCVR and the LCVR, the entire heavy chain, the entire light chain, or the entire heavy chain and light chain are WO 2009/140124 PCT/US2009/043063 -11 limited by a particular sequence as shown by a SEQ ID NO: herein is further characterized by having a KD in an assay that evaluates the binding activities of the antibodies by Surface Plasmon Reasonance (BlAcore) as described herein between 15 nM and 0.05 nM in the BlAcore assay as described herein. Further preferred, an antibody 5 of the present invention wherein all six CDRs, the HCVR, the LCVR, the HCVR and the LCVR, the entire heavy chain, the entire light chain, or the entire heavy chain and light chain are limited by a particular sequence as shown by a SEQ ID NO: herein is further characterized by having a KD in an assay that evaluates the binding activities of the antibodies by Surface Plasmon Reasonance (BlAcore) as described herein between 1.0 10 nM and 0.05 nM in the BlAcore assay as described herein. More preferably, an antibody of the present invention wherein all six CDRs, the HCVR, the LCVR, the HCVR and the LCVR, the entire heavy chain, the entire light chain, or the entire heavy chain and light chain are limited by a particular sequence as shown by a SEQ ID NO: herein is further characterized by having anti-tumorigenesis 15 activity by preventing tumor growth in a tumor xenograft model using NOD/SCID mice and human non-Hodgkin's lymphoma Namalwa cells as described herein when administered at 10 mg/kg, and even more preferably when administered at 1 mg/kg. Most preferably, an antibody of the present invention wherein all six CDRs, the HCVR, the LCVR, the HCVR and the LCVR, the entire heavy chain, the entire light 20 chain, or the entire heavy chain and light chain are limited by a particular sequence as shown by a SEQ ID NO: herein is further characterized by inducing apoptosis of tumor cells in an apoptosis assay as described herein. More preferred, an antibody of the present invention wherein all six CDRs, the HCVR, the LCVR, the HCVR and the LCVR, the entire heavy chain, the entire light chain, or the entire heavy chain and light 25 chain are limited by a particular sequence as shown by a SEQ ID NO: herein is further characterized by inducing nuclear fragmentation and activation of caspase 3, hallmarks of apoptosis, in multiple tumor cells including Namalwa and CEM cells when administered between 2 pg/mL and 10 pg/mL. 30 EXAMPLES Antibodies I, II, III, IV, and V can be made and purified as follows. An appropriate host cell, such as HEK 293 EBNA or CHO, is either transiently or stably WO 2009/140124 PCT/US2009/043063 -12 transfected with an expression system for secreting antibodies using an optimal predetermined HC:LC vector ratio or a single vector system encoding both HC, such as SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, or SEQ ID NO: 27 and LC, such as SEQ ID NO: 28. Clarified media, into which the antibody has been 5 secreted, is purified using any of many commonly-used techniques. For example, the medium may be conveniently applied to a Protein A or G Sepharose FF column that has been equilibrated with a compatible buffer, such as phosphate buffered saline (pH 7.4). The column is washed to remove nonspecific binding components. The bound antibody is eluted, for example, by pH gradient (such as 0.1 M sodium phosphate buffer pH 6.8 to 10 0.1 M sodium citrate buffer pH 2.5). Antibody fractions are detected, such as by SDS PAGE, and then are pooled. Further purification is optional, depending on the intended use. The antibody may be concentrated and/or sterile filtered using common techniques. Soluble aggregate and multimers may be effectively removed by common techniques, including size exclusion, hydrophobic interaction, ion exchange, or hydroxyapatite 15 chromatography. The purity of the antibody after these chromatography steps is greater than 99%. The product may be immediately frozen at -70'C or may be lyophilized. The amino acid sequences for these antibodies are provided below. SEQ ID NOs Antibody Heavy Light HCVR LCVR Chain Chain I 17 22 11 16 II 18 22 12 16 III 19 22 13 16 IV 20 22 14 16 V 21 22 15 16 20 Antibody HCDR1 HCDR2 HCDR3 LCDR1 LCDR2 LCDR3 I 1 2 3 8 9 10 WO 2009/140124 PCT/US2009/043063 -13 II 1 4 3 8 9 10 III 1 5 3 8 9 10 IV 1 6 3 8 9 10 V 1 7 3 8 9 10 Human CXCR4/12 I-SDF-1a Binding Inhibition Assay SDF- 1 binding to CXCR4 is the first step in activating the CXCR4 intracellular signaling pathway. To determine if an antibody can block the interaction of SDF-1 and 5 CXCR4, human leukemia CCRF-CEM cells expressing endogenous CXCR4 are used in an 125 I-labeled SDF-la binding assay. The assay is performed in a 96-well U-bottom, non-treated polystyrene plate. The binding assay buffer is prepared with RPMI 1640 medium containing 10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES), pH 7.5, and 0.2% bovine serum albumin (BSA). Briefly, 200 pL reaction 10 mixtures containing 300 pM ligand (60 pM 125 -SDF-la and 240 pM cold SDF-la), different concentrations of the test antibody in assay buffer, 100,000 human CCRF-CEM cells, and 0.5 mg scintillation proximity assay (SPA) beads are incubated at room temperature for 2 hours. Plates are then counted in a liquid scintillation and luminescence counter in SPA mode. CXCR4 antagonists decrease the bound radioactivity in this assay 15 in a dose-dependent manner. The inhibitory potency (IC 50 ) of a test antibody is calculated using GraphPad Prism software, based on the dose-dependent decrease of bound radioactivity. Antibodies exemplified herein exhibit an IC 50 value of 10 nM or less in this assay. For example, the antibody III exhibits an average IC50 of 0.45 nM in this assay. The data 20 demonstrate that antibodies exemplified herein bind to human CXCR4 with high affinity and inhibit human CXCR4 binding to SDF- 1. Chemotaxis Assay CXCR4/SDF- 1 interaction regulates migration (chemotaxis) of cells bearing 25 CXCR4 on their surface. To determine the antagonist and cellular activities of a test antibody, a chemotaxis assay using human histiocytic lymphoma U937 cells that express endogenous CXCR4 is employed. Briefly, U937 cells, grown in Dulbecco's Modified WO 2009/140124 PCT/US2009/043063 -14 Eagle Medium (D-MEM) containing 10% fetal bovine serum, 1% Minimum Essential Medium (MEM) sodium pyruvate solution, 1% MEM nonessential amino acids, and 1% L-glutamine, are harvested and washed once with chemotaxis assay buffer (1x RPMI medium containing 10 mM HEPES, pH 7.5, and 0.3% BSA.) After washing, cells are 5 resuspended in assay buffer at a concentration of 5 x 106 cells/mL. The assay is performed in a 96-well cell migration plate. Generally, 50 PL of cell mixture with or without test antibody, ranging from 0.5 pg/mL to 50 pg/mL, is plated on the upper chamber, and 30 pL of SDF-la (10 ng/mL) prepared in Ix chemotaxis assay buffer is added to the lower chamber. After assembly, the plate is incubated for 2.5 hours at 37'C 10 under 5% carbon dioxide. Following the incubation, 5 pL of cell proliferation solution is added into the lower chamber. The plate is then incubated for 60 minutes at 37'C, and the migrated cells are detected by measuring the absorbance at 492 nm with a microplate reader. CXCR4 antagonists inhibit cell migration, reducing the absorbance reading. The inhibitory potency (IC 50 ) of a test antibody in this assay is calculated using GraphPad 15 Prism software, based on the dose-dependent decrease of absorbance at 492 nm. Antibodies exemplified herein exhibit an average IC50 value of 30 nM or less in this assay. The antibody III exhibits an average IC50 value of 5.90 nM in this assay. The data demonstrate that antibodies exemplified herein bind to human CXCR4 with high affinity and inhibit human CXCR4 binding to SDF-1. 20 Evaluation of binding activities of anti-CXCR4 antibodies by Surface Plasmon Reasonance (BIAcore) A Biacore@ 2000 instrument is used to measure binding kinetics and affinity. The Biacore@ utilizes the optical properties of surface plasmon resonance to detect 25 alteration in protein concentration of interacting molecules within a dextran biosensor matrix. Except as noted, all reagents and materials are purchased from Biacore@ AB (Upsala, Sweden). All measurements are performed at 4'C. The binding experiment is performed essentially as described in Stenlund et al (Stenlund P, Babcock GJ, Sodroski J, Myszka DG. (2003) Capture and reconstitution of G protein-coupled receptors on a 30 biosensor surface. Anal Biochem. 316(2):243-50) and Navratilo et al (Navratilova I, Sodroski J, Myszka DG. (2005) Solubilization, stabilization, and purification of WO 2009/140124 PCT/US2009/043063 -15 chemokine receptors using biosensor technology. Anal Biochem. 339(2):271-81). Running buffer is 50 mM HEPES, 5 mM magnesium chloride, 1 mM calcium chloride, 150 mM sodium chloride, 2 mg/mL BSA, pH 7.5. The human CXCR4 receptor with a C terminal linear C9 peptide tag (SEQ ID NO: 29), is cloned and overexpressed in canine 5 thymocyte Cf2Th cells in the same manner as described previously by Mirzabekov et al (Mirzabekov, N. Bannert, M. Farzan, W. Hofmann, P. Kolchinsky, L. Wu, R. Wyatt and J. Sodroski- Enhanced expression, native purification, and characterization of CCR5, a principal HIV-1 coreceptor. J. Biol. Chem. 274 (1999), pp. 28745-28750). The C terminal linear C9 peptide tag is recognized by the 1D4 monoclonal antibody (D.D. 10 Oprian, R.S. Molday, R.J. Kaufman and H.G. Khorana, Expression of a synthetic bovine rhodopsin gene in monkey kidney cells. Proc. Natl. Acad. Sci. USA 84 (1987), pp. 8874 8878). Binding is evaluated using multiple analytical cycles as follows. 1D4 Mab (Monoclonal clone 1D4, University of British Columbia) is immobilized to a CM5 chip 15 via amine coupling (about 10,000-20,000 Resonance Units antibody). Cells are resuspended in 20 mM tris(hydroxymethyl)aminomethane (pH 7.0), 0.1 M ammonium sulphate, 10% glycerol, 5 mM magnesium chloride, 1 mM calcium chloride, plus complete ethylenediaminetetraacetic acid-free protease inhibitor tablet. 4x10 6 cells/mL final for injection onto the chip (i.e. 2.0x10 6 cells, 0.5 mL final volume) are used. 20 Transfected cells and running buffer with detergent (2% cholesteryl hemisuccinate ester, 10% dodecyl maltoside, 10% 3-[(3-Cholamidopropyl)dimethylammonio]-1 propanesulfonate) at a ratio of 5:1 (cells to buffer volume ratio) are transferred into an auto-mixer. This mixture is incubated for 10 minutes. After incubation 150 PL solubilized receptor is injected over 1D4 surface at a flow rate of 20 pL/minute. The 25 sample loop is then washed with running buffer. This is followed by an injection of 20 pL of antibody at flow rate of 100 pL /minute. The chip is then regenerated with two 10 second pulses of 10 mM sodium hydroxide + 1% n-octyl-j-D-glucopyranoside at 100 pL/minute. Association rate constants ("ko 1 ") and dissociation rate constants ("kff") for each cycle are evaluated using a "1:1 with mass transfer" binding model in the 30 BlAevaluation software. "KD" is the dissociation constant and it is calculated by the formula: kff/k. = KD. The binding parameters are summarized below. The data WO 2009/140124 PCT/US2009/043063 -16 demonstrate that antibodies exemplified herein bind to human CXCR4 with high affinity and inhibit human CXCR4 binding to SDF- 1. Antibody Kon (M 1 s ) Ko f (s 1 ) KD (nM) I 2.36 x 106 1.61 x 10-3 0.68 II 2.50 x 10 6 1.81 x 10- 3 0.72 III 1.12 x 10 6 1.72 x 10- 3 1.54 IV 7.74 x 105 3.98 x 10-3 5.14 V 1.91 x 10 6 1.68 x 10- 3 0.88 5 Anti-Tumor Activity in a SCID/Namalwa Xenograft Model SDF-1/CXCR4 interaction appears to play an important role in multiple stages of tumorigenesis, including tumor growth, invasion, angiogenesis, and metastasis. To evaluate in vivo anti-tumor activity of a test antibody in cancer, a tumor xenograft model using NOD/SCID mice and human non-Hodgkin's lymphoma Namalwa cells is 10 employed. Briefly, 200,000 Namalwa cells mixed with matrigel (1:1) are implanted subcutaneously into the rear flank of the animals. The implanted tumor cells grow as solid tumors, the dimensions of which can be continuously monitored and measured using a caliper. To determine the in vivo efficacy of a test antibody in this model, animals (10/group) are treated with different doses of test antibodies dissolved in saline or 15 phosphate buffered saline, 48 hours post tumor cell implantation. Antibodies are dosed subcutaneously in the range of 1 pg/mouse, 10 pg/mouse, and 100 pg/mouse, and tumor volume and body weight are determined every 2 or 3 days. The studies last generally 3-4 weeks, depending on the tumor growth. The anti-tumor growth activity of a test antibody is determined by the percent reduction in tumor volume in treatment groups compared to 20 tumor volume in control groups treated with vehicle alone. Antibody I inhibits tumor growth in this assay when administered at 10pg/mouse, which is approximately 0.4 mg/kg. The data demonstrate that Antibody I has tumorigenesis activity by preventing tumor growth. 25 WO 2009/140124 PCT/US2009/043063 -17 SCID/Namalwa Hematological Lymphoma Model To further investigate anti-tumor activity of CXCR4 antibody in lymphoma, a hematological lymphoma model is established by injecting 200,000 Namalwa cells into SCID mice via tail vein. Generally, the mice injected with tumor cells die in 5-6 weeks. 5 To test efficacy of the antibody in this model, animals (10 each group) are treated with 30 pg/mouse or 100 pg/mouse of test antibody 24 hours post tumor cell injection. The antibody is dosed subcutaneously once every 4 days for 6 weeks, and the animal survival is recorded on daily basis. Antibody I treatment groups have shown statistically significant survival benefit 10 when compared with vehicle and isotype IgG control groups in this hematological lymphoma model. Anti-Tumor Activity in a SCID/CEM Xenograft Model To evaluate in vivo anti-tumor activity of a test antibody in cancer, a tumor 15 xenograft model using NOD/SCID mice and CEM cells is employed. Briefly, 5.0x10 6 CEM cells mixed with matrigel (1:1) are implanted subcutaneously into the rear flank of the animals. The implanted tumor cells grow as solid tumors which can be continuously monitored and measured by caliber. To determine the efficacy of a test antibody in this model, animals (10 each group) are treated with 10 pg/mouse, 30 pg/mouse, or 100 20 pg/mouse of test antibody 24 hours post tumor cell implantation. The antibody is dosed subcutaneously once every 4 days, and the tumor volume and body weight are measured every 2 or 3 days. A dose-dependent tumor growth inhibition is observed among Antibody I treatment groups compared with vehicle and isotype IgG control groups. Antibody I at 25 all three doses inhibits tumor growth significantly. Apoptosis Assay To investigate if CXCR4 antibodies induce apoptosis, multiple tumor cell lines expressing high levels of CXCR4 are treated with test antibody. The cells are treated with 30 different concentrations of test antibody for 2-4 days in their growth medium with 1% or 10 % FBS. After treatment, cells are fixed with 3.7% formaldehyde and washed in D PBS. Cells are permeabilized with 0.1% Triton X-100 in D-PBS, washed and blocked in WO 2009/140124 PCT/US2009/043063 -18 D-PBS containing 1% BSA. Cells are then incubated for 1 hour with rabbit anti-activated Caspase3 polyclonal antibody (Cat# 557135 BD Biosciences, NC) diluted in D-PBS with 1% BSA. Cells are washed 2 times with D-PBS then incubated for 1 hour with Alexa Fluor 488 goat anti Rabbit IgG (Invitrogen, Carlsbad, CA) and 200ng/mL Hoechst 33342 5 (Invitrogen, Carlsbad, CA) diluted in D-PBS with 1% BSA. Stained plates are scanned using ArrayScan Vti (Cellomics, Pittsburgh, Pennsylvania) and the Target Activation bioapplication is used for quantitation of fluorescent signal. The results demonstrate that Antibody I induces nuclear fragmentation and activation of caspase 3 in multiple tumor cells including Namalwa and CEM cells. 10 Nuclear fragmentation and caspase 3 activation are hallmarks of apoptosis. Therefore, the data demonstrate that Antibody I induces apoptosis of tumor cells when administered between 2 pg/mL and 10 pg/mL. To further confirm that Antibody I induces apoptosis, annexin V changes are investigated by flow cytometry in Namalwa cells after treatment with test antibody or 15 isotype IgG control. Antibody I induces a dose-dependent increase of annexin V, while isotype IgG has no effect. Furthermore, Antibody I induces apoptosis which is also observed in CEM xenograft tumors by TUNEL staining. 20 WO 2009/140124 PCT/US2009/043063 -19 SEQ ID Listing Heavy Chain CDRs 5 SEQ ID NO:1 GFTSTDYYFS SEQ ID NO:2 FIRTKSKGYTTEYSGSVKG SEQ ID NO:3 EPITTDPRDY SEQ ID NO:4 FIRSKSKGYTTEYSGSVKG SEQ ID NO:5 FIRYKSKGYTTEYSGSVKG 10 SEQ ID NO:6 FIRNKRKGYTTEYSGSVKG SEQ ID NO:7 FIRHKSKGYTTEYSGSVKG Light Chain CDRs 15 SEQ ID NO:8 KSSQSLFNSRTRKKYLA SEQ ID NO:9 WASKRKS SEQ ID NO:10 KQSRFLRA 20 Heavy Chain Variable Regions SEQ ID NO:11 EVQLVESGGGLVQPGGSLRLSCAASGFTSTDYYFSWVRQAPGKGLEWVGFIRTK 25 SKGYTTEYSGSVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCAREPITTDPRD YWGQGTLVTVSS SEQ ID NO:12 EVQLVESGGGLVQPGGSLRLSCAASGFTSTDYYFSWVRQAPGKGLEWVGFIRSK 30 SKGYTTEYSGSVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCAREPITTDPRD YWGQGTLVTVSS SEQ ID NO:13 EVQLVESGGGLVQPGGSLRLSCAASGFTSTDYYFSWVRQAPGKGLEWVGFIRYK 35 SKGYTTEYSGSVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCAREPITTDPRD YWGQGTLVTVSS SEQ ID NO:14 EVQLVESGGGLVQPGGSLRLSCAASGFTSTDYYFSWVRQAPGKGLEWVGFIRNK 40 RKGYTTEYSGSVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCAREPITTDPRD YWGQGTLVTVSS SEQ ID NO:15 EVQLVESGGGLVQPGGSLRLSCAASGFTSTDYYFSWVRQAPGKGLEWVGFIRHK 45 SKGYTTEYSGSVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCAREPITTDPRD

YWGQGTLVTVSS

WO 2009/140124 PCT/US2009/043063 -20 Light Chain Variable Regions SEQ ID NO:16 DIVMTQSPDSLAVSLGERATINCKSSQSLFNSRTRKKYLAWYQQKPGQPPKLLIY 5 WASKRKSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSRFLRAFGQGTKLE IK Complete Heavy Chains 10 SEQ ID NO:17 EVQLVESGGGLVQPGGSLRLSCAASGFTSTDYYFSWVRQAPGKGLEWVGFIRTK SKGYTTEYSGSVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCAREPITTDPRD YWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNS 15 GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRV ESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQ FNWYVDGVEVINAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK GLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHY 20 TQKSLSLSLG SEQ ID NO:18 EVQLVESGGGLVQPGGSLRLSCAASGFTSTDYYFSWVRQAPGKGLEWVGFIRSK SKGYTTEYSGSVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCAREPITTDPRD 25 YWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNS GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRV ESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQ FNWYVDGVEVINAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK GLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWE 30 SNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHY TQKSLSLSLG SEQ ID NO:19 EVQLVESGGGLVQPGGSLRLSCAASGFTSTDYYFSWVRQAPGKGLEWVGFIRYK 35 SKGYTTEYSGSVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCAREPITTDPRD YWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNS GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRV ESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQ FNWYVDGVEVINAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK 40 GLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHY TQKSLSLSLG SEQ ID NO:20 45 EVQLVESGGGLVQPGGSLRLSCAASGFTSTDYYFSWVRQAPGKGLEWVGFIRNK RKGYTTEYSGSVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCAREPITTDPRD

YWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNS

WO 2009/140124 PCT/US2009/043063 -21 GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRV ESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQ FNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK GLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWE 5 SNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHY TQKSLSLSLG SEQ ID NO:21 EVQLVESGGGLVQPGGSLRLSCAASGFTSTDYYFSWVRQAPGKGLEWVGFIRHK 10 SKGYTTEYSGSVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCAREPITTDPRD YWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNS GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRV ESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQ FNWYVDGVEVINAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK 15 GLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHY TQKSLSLSLG 20 Complete Light Chain SEQ ID NO:22 DIVMTQSPDSLAVSLGERATINCKSSQSLFNSRTRKKYLAWYQQKPGQPPKLLIY WASKRKSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSRFLRAFGQGTKLE 25 IKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Nucleotide Sequences - Heavy Chain Variable Region 30 SEQ ID NO:23 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGAGGGTCCC TGAGACTCTCCTGTGCAGCCTCTGGCTTCACCAGTACCGACTACTACTTTAGC TGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTTGGCTTCATCCGGA 35 CGAAGTCGAAGGGCTACACCACCGAGTACAGCGGCAGCGTGAAGGGCAGAT TCACCATCTCAAGAGATGATTCAAAGAACTCACTGTACCTGCAGATGAACAG CCTGAAAACCGAGGACACGGCCGTGTATTACTGTGCTAGAGAGCCCATCACC ACCGACCCTCGGGACTACTGGGGCCAAGGGACCCTGGTCACCGTCTCCTCA 40 SEQ ID NO:24 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGAGGGTCCC TGAGACTCTCCTGTGCAGCCTCTGGCTTCACCAGTACCGACTACTACTTTAGC TGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTTGGCTTCATCCGGT CTAAGTCGAAGGGCTACACCACCGAGTACAGCGGCAGCGTGAAGGGCAGATT 45 CACCATCTCAAGAGATGATTCAAAGAACTCACTGTACCTGCAGATGAACAGC CTGAAAACCGAGGACACGGCCGTGTATTACTGTGCTAGAGAGCCCATCACCA

CCGACCCTCGGGACTACTGGGGCCAAGGGACCCTGGTCACCGTCTCCTCA

WO 2009/140124 PCT/US2009/043063 -22 SEQ ID NO:25 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGAGGGTCCC TGAGACTCTCCTGTGCAGCCTCTGGCTTCACCAGTACCGACTACTACTTTAGC 5 TGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTTGGCTTCATCCGGT ATAAGTCGAAGGGCTACACCACCGAGTACAGCGGCAGCGTGAAGGGCAGATT CACCATCTCAAGAGATGATTCAAAGAACTCACTGTACCTGCAGATGAACAGC CTGAAAACCGAGGACACGGCCGTGTATTACTGTGCTAGAGAGCCCATCACCA CCGACCCTCGGGACTACTGGGGCCAAGGGACCCTGGTCACCGTCTCCTCA 10 SEQ ID NO:26 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGAGGGTCCC TGAGACTCTCCTGTGCAGCCTCTGGCTTCACCAGTACCGACTACTACTTTAGC TGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTTGGCTTCATCCGGA 15 ACAAGCGGAAGGGCTACACCACCGAGTACAGCGGCAGCGTGAAGGGCAGAT TCACCATCTCAAGAGATGATTCAAAGAACTCACTGTACCTGCAGATGAACAG CCTGAAAACCGAGGACACGGCCGTGTATTACTGTGCTAGAGAGCCCATCACC ACCGACCCTCGGGACTACTGGGGCCAAGGGACCCTGGTCACCGTCTCCTCA 20 SEQ ID NO:27 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGAGGGTCCC TGAGACTCTCCTGTGCAGCCTCTGGCTTCACCAGTACCGACTACTACTTTAGC TGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTTGGCTTCATCCGGC ACAAGTCGAAGGGCTACACCACCGAGTACAGCGGCAGCGTGAAGGGCAGAT 25 TCACCATCTCAAGAGATGATTCAAAGAACTCACTGTACCTGCAGATGAACAG CCTGAAAACCGAGGACACGGCCGTGTATTACTGTGCTAGAGAGCCCATCACC ACCGACCCTCGGGACTACTGGGGCCAAGGGACCCTGGTCACCGTCTCCTCA 30 Nucleotide Sequences - Light Chain Variable Region SEQ ID NO:28 GACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAG GGCCACCATCAACTGCAAGAGCAGCCAGAGCCTGTTCAACAGCCGGACCCGG 35 AAGAAGTACCTGGCCTGGTACCAGCAGAAACCAGGACAGCCTCCTAAGCTGC TCATTTACTGGGCCAGCAAGAGAAAGAGCGGGGTCCCTGACCGATTCAGTGG CAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGGCTGAA GATGTGGCAGTTTATTACTGTAAGCAGAGCCGTTTTCTGAGAGCCTTTGGCCA AGGGACCAAGCTGGAGATCAAA 40 C-Terminal Linear C9 Peptide Tag for Human CXCR4 Receptor SEQ ID NO:29 TETSQVAPA 45 WO 2009/140124 PCT/US2009/043063 -23 Human CXCR4 SEQ ID NO:30 MEGISSIPLPLLQIYTSDNYTEEMGSGDYDSMKEPCFREENANFNKIFLPTIYSIIFL 5 TGIVGNGLVILVMGYQKKLRSMTDKYRLHLSVADLLFVITLPFWAVDAVANWY FGNFLCKAVHVIYTVNLYSSVLILAFISLDRYLAIVHATNSQRPRKLLAEKVVYVG VWIPALLLTIPDFIFANVSEADDRYICDRFYPNDLWVVVFQFQHIMVGLILPGIVIL SCYCIIISKLSHSKGHQKRKALKTTVILILAFFACWLPYYIGISIDSFILLEIIKQGCEF ENTVHKWISITEALAFFHCCLNPILYAFLGAKFKTSAQHALTSVSRGSSLKILSKG 10 KRGGHSSVSTESESSSFHSS Human CXCR4 isoform A 15 SEQ ID NO:31 MSIPLPLLQIYTSDNYTEEMGSGDYDSMKEPCFREENANFNKIFLPTIYSIIFLTGIV GNGLVILVMGYQKKLRSMTDKYRLHLSVADLLFVITLPFWAVDAVANWYFGNF LCKAVHVIYTVNLYSSVLILAFISLDRYLAIVHATNSQRPRKLLAEKVVYVGVWIP ALLLTIPDFIFANVSEADDRYICDRFYPNDLWVVVFQFQHIMVGLILPGIVILSCYC 20 IIISKLSHSKGHQKRKALKTTVILILAFFACWLPYYIGISIDSFILLEIIKQGCEFENTV HKWISITEALAFFHCCLNPILYAFLGAKFKTSAQHALTSVSRGSSLKILSKGKRGG HSSVSTESESSSFHSS 25 Human CXCR4 isoform B SEQ ID NO:32 MEGISIYTSDNYTEEMGSGDYDSMKEPCFREENANFNKIFLPTIYSIIFLTGIVGNG LVILVMGYQKKLRSMTDKYRLHLSVADLLFVITLPFWAVDAVANWYFGNFLCK 30 AVHVIYTVNLYSSVLILAFISLDRYLAIVHATNSQRPRKLLAEKVVYVGVWIPALL LTIPDFIFANVSEADDRYICDRFYPNDLWVVVFQFQHIMVGLILPGIVILSCYCIIIS KLSHSKGHQKRKALKTTVILILAFFACWLPYYIGISIDSFILLEIIKQGCEFENTVHK WISITEALAFFHCCLNPILYAFLGAKFKTSAQHALTSVSRGSSLKILSKGKRGGHSS VSTESESSSFHSS 35 Human SDF-1 a SEQ ID NO:33 40 KPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKL

KWIQEYLEKALNK

Claims

1. A human engineered antibody or a binding fragment thereof, that binds human CXCR4, and which: 5 a. inhibits binding of human SDF-la (SEQ ID NO:33) to CXCR4 with an IC 50 for human CXCR4 between 10 nM and 0.05 nM in a human CXCR4/ 125 1-SDF-1a binding inhibition assay as described herein; b. inhibits migration of cells bearing CXCR4 on their surface with an IC 50 between 30 nM and 0.3 nM in the chemotaxis assay as described herein; 10 and c. exhibits an affinity, KD between 15 nM and 0.05 nM in the Surface Plasmon Reasonance (BlAcore) assay as described herein.

2. The antibody of Claim 1, which inhibits binding of human SDF-Ia (SEQ ID NO:33) to CXCR4 with an IC 50 for human CXCR4 between 0.5 nM and 0.05 15 nM.

3. The antibody of either Claim 1 or Claim 2, which inhibits migration of cells bearing CXCR4 on their surface with an IC 50 between 3.0 nM and 0.3 nM.

4. The antibody of any one of Claims I to 3, which exhibits an affinity, KD between 1.0 nM and 0.05 nM. 20

5. The antibody of any one of Claims 1 to 4, which exhibits anti-tumorigenesis activity by preventing tumor growth in a tumor xenograft model as described herein when administered at 1 mg/kg.

6. The antibody of any one of Claims I to 5, which induces apoptosis of tumor cells in an apoptosis assay as described herein when administered between 2 25 pg/mL and 10 pg/mL.

7. A human engineered antibody or a binding fragment thereof, that comprises a light chain comprising a light chain variable region that comprises framework regions, CDRL1 having the amino acid sequence of SEQ ID NO:8, CDRL2 having the amino acid sequence of SEQ ID NO:9, and CDRL3 having the 30 amino acid sequence of SEQ ID NO: 10, and a heavy chain comprising a heavy chain variable region that comprises framework regions, CDRIH1 having the amino acid sequence of SEQ ID NO: 1, CDRH3 having the amino acid WO 2009/140124 PCT/US2009/043063 -25 sequence of SEQ ID NO:3, and CDRH2 having an amino sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, wherein the antibody binds to human CXCR4. 5

8. The antibody of Claim 7, wherein a light chain comprises the amino acid sequence of SEQ ID NO:16.

9. The antibody of either Claim 7 or Claim 8, wherein a heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15.

10 10. The antibody of any one of Claims 7 to 9, wherein a light chain comprises the amino acid sequence of SEQ ID NO:22.

11. The antibody of any one of Claims 7 to 10, wherein a heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO:20, and SEQ ID NO:21. 15

12. The antibody of any one of Claims 7 to 11, which is selected from the group consisting of an antibody comprising SEQ ID NO:17 and SEQ ID NO:22, an antibody comprising SEQ ID NO:18 and SEQ ID NO:22, an antibody comprising SEQ ID NO:19 and SEQ ID NO:22, an antibody comprising SEQ ID NO:20 and SEQ ID NO:22, and an antibody comprising SEQ ID NO:21 20 and SEQ ID NO:22.

13. The antibody of any one of Claims 7 to 12 that comprises two light chains of SEQ ID NO: 22, and two heavy chains of SEQ ID NO: 17.

14. A pharmaceutical composition comprising an antibody of any one of Claims 1 to 13 in combination with one or more pharmaceutically acceptable carriers, 25 diluents, or excipients.

15. An antibody of any one of Claims I to 13 for use in therapy.

16. An antibody of any one of Claims I to 13 for use in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis.

17. The use of an antibody of any one of Claims I to 13 in the manufacture of a 30 medicament for the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis. WO 2009/140124 PCT/US2009/043063 -26

18. A method of treating tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis comprising administering to a patient in need thereof a therapeutically effective amount of an antibody of any one of Claims I to 13. 5

19. An antibody of any one of Claims 1 to 13 for use in the treatment of a cancer selected from the group consisting of breast cancer, pancreatic cancer, melanoma, prostate cancer, kidney cancer, neuroblastoma, non-Hodgkin's lymphoma, lung cancer, ovarian cancer, colorectal cancer, multiple myeloma, glioblastoma multiforme, and leukemia. 10

20. The use of an antibody of any one of Claims I to 13 in the manufacture of a medicament for the treatment of a cancer selected from the group consisting of breast cancer, pancreatic cancer, melanoma, prostate cancer, kidney cancer, neuroblastoma, non-Hodgkin's lymphoma, lung cancer, ovarian cancer, colorectal cancer, multiple myeloma, glioblastoma multiforme, and leukemia. 15

21. A method of treating a cancer selected from the group consisting of breast cancer, pancreatic cancer, melanoma, prostate cancer, kidney cancer, neuroblastoma, non-Hodgkin's lymphoma, lung cancer, ovarian cancer, colorectal cancer, multiple myeloma, glioblastoma multiforme, and leukemia, comprising administering to a patient in need thereof a therapeutically 20 effective amount of an antibody of any one of Claims I to 13. 969450Seq.TXT SEQUENCE LISTING <110> Eli Lilly and Company <120> ANTI-CXCR4 ANTIBODIES <130> X17693 <150> 61/053192 <151> 2008-05-14 <160> 33 <170> PatentIn version 3.5 <210> 1 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 1 Gly Phe Thr Ser Thr Asp Tyr Tyr Phe Ser 1 5 10 <210> 2 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 2 Phe Ile Arg Thr Lys Ser Lys Gly Tyr Thr Thr Glu Tyr Ser Gly Ser 1 5 10 15 Val Lys Gly <210> 3 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 3 Glu Pro Ile Thr Thr Asp Pro Arg Asp Tyr 1 5 10 <210> 4 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct Page 1 969450Seq.TXT <400> 4 Phe Ile Arg Ser Lys Ser Lys Gly Tyr Thr Thr Glu Tyr Ser Gly Ser 1 5 10 15 Val Lys Gly <210> 5 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 5 Phe Ile Arg Tyr Lys Ser Lys Gly Tyr Thr Thr Glu Tyr Ser Gly Ser 1 5 10 15 Val Lys Gly <210> 6 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 6 Phe Ile Arg Asn Lys Arg Lys Gly Tyr Thr Thr Glu Tyr Ser Gly Ser 1 5 10 15 Val Lys Gly <210> 7 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 7 Phe Ile Arg His Lys Ser Lys Gly Tyr Thr Thr Glu Tyr Ser Gly Ser 1 5 10 15 Val Lys Gly <210> 8 <211> 17 <212> PRT Page 2 969450Seq.TXT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 8 Lys Ser Ser Gln Ser Leu Phe Asn Ser Arg Thr Arg Lys Lys Tyr Leu 1 5 10 15 Ala <210> 9 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 9 Trp Ala Ser Lys Arg Lys Ser 1 5 <210> 10 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 10 Lys Gln Ser Arg Phe Leu Arg Ala 1 5 <210> 11 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 11 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ser Thr Asp Tyr 20 25 30 Tyr Phe Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Phe Ile Arg Thr Lys Ser Lys Gly Tyr Thr Thr Glu Tyr Ser Gly 50 55 60 Page 3 969450Seq.TXT Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Ala Arg Glu Pro Ile Thr Thr Asp Pro Arg Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 12 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 12 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ser Thr Asp Tyr 20 25 30 Tyr Phe Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Phe Ile Arg Ser Lys Ser Lys Gly Tyr Thr Thr Glu Tyr Ser Gly 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Ala Arg Glu Pro Ile Thr Thr Asp Pro Arg Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 13 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 13 Page 4 969450Seq.TXT Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ser Thr Asp Tyr 20 25 30 Tyr Phe Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Phe Ile Arg Tyr Lys Ser Lys Gly Tyr Thr Thr Glu Tyr Ser Gly 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Ala Arg Glu Pro Ile Thr Thr Asp Pro Arg Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 14 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 14 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ser Thr Asp Tyr 20 25 30 Tyr Phe Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Phe Ile Arg Asn Lys Arg Lys Gly Tyr Thr Thr Glu Tyr Ser Gly 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Ala Arg Glu Pro Ile Thr Thr Asp Pro Arg Asp Tyr Trp Gly Page 5 969450Seq.TXT 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 15 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 15 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ser Thr Asp Tyr 20 25 30 Tyr Phe Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Phe Ile Arg His Lys Ser Lys Gly Tyr Thr Thr Glu Tyr Ser Gly 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Ala Arg Glu Pro Ile Thr Thr Asp Pro Arg Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 16 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 16 Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Phe Asn Ser 20 25 30 Arg Thr Arg Lys Lys Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Page 6 969450Seq.TXT 35 40 45 Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Lys Arg Lys Ser Gly Val 50 55 60 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Lys Gln 85 90 95 Ser Arg Phe Leu Arg Ala Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 17 <211> 447 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 17 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ser Thr Asp Tyr 20 25 30 Tyr Phe Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Phe Ile Arg Thr Lys Ser Lys Gly Tyr Thr Thr Glu Tyr Ser Gly 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Ala Arg Glu Pro Ile Thr Thr Asp Pro Arg Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 Page 7 969450Seq.TXT Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His 195 200 205 Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly 210 215 220 Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro 260 265 270 Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Page 8 969450Seq.TXT Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440 445 <210> 18 <211> 447 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 18 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ser Thr Asp Tyr 20 25 30 Tyr Phe Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Phe Ile Arg Ser Lys Ser Lys Gly Tyr Thr Thr Glu Tyr Ser Gly 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Ala Arg Glu Pro Ile Thr Thr Asp Pro Arg Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His 195 200 205 Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Page 9 969450Seq.TXT 210 215 220 Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro 260 265 270 Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440 445 <210> 19 <211> 447 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 19 Page 10 969450Seq.TXT Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ser Thr Asp Tyr 20 25 30 Tyr Phe Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Phe Ile Arg Tyr Lys Ser Lys Gly Tyr Thr Thr Glu Tyr Ser Gly 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Ala Arg Glu Pro Ile Thr Thr Asp Pro Arg Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His 195 200 205 Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly 210 215 220 Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro 260 265 270 Page 11 969450Seq.TXT Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440 445 <210> 20 <211> 447 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 20 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ser Thr Asp Tyr 20 25 30 Tyr Phe Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Phe Ile Arg Asn Lys Arg Lys Gly Tyr Thr Thr Glu Tyr Ser Gly Page 12 969450Seq.TXT 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Ala Arg Glu Pro Ile Thr Thr Asp Pro Arg Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His 195 200 205 Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly 210 215 220 Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro 260 265 270 Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Page 13 969450Seq.TXT 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440 445 <210> 21 <211> 447 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 21 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ser Thr Asp Tyr 20 25 30 Tyr Phe Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Phe Ile Arg His Lys Ser Lys Gly Tyr Thr Thr Glu Tyr Ser Gly 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Ala Arg Glu Pro Ile Thr Thr Asp Pro Arg Asp Tyr Trp Gly 100 105 110 Page 14 969450Seq.TXT Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His 195 200 205 Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly 210 215 220 Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro 260 265 270 Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Page 15 969450Seq.TXT Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440 445 <210> 22 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400>

22 Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Phe Asn Ser 20 25 30 Arg Thr Arg Lys Lys Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Lys Arg Lys Ser Gly Val 50 55 60 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Lys Gln 85 90 95 Ser Arg Phe Leu Arg Ala Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Page 16 969450Seq.TXT 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 23 <211> 363 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Construct <400> 23 gaggtgcagc tggtggagtc tgggggaggc ttggtccagc ctggagggtc cctgagactc 60 tcctgtgcag cctctggctt caccagtacc gactactact ttagctgggt ccgccaggct 120 ccagggaagg ggctggagtg ggttggcttc atccggacga agtcgaaggg ctacaccacc 180 gagtacagcg gcagcgtgaa gggcagattc accatctcaa gagatgattc aaagaactca 240 ctgtacctgc agatgaacag cctgaaaacc gaggacacgg ccgtgtatta ctgtgctaga 300 gagcccatca ccaccgaccc tcgggactac tggggccaag ggaccctggt caccgtctcc 360 tca 363 <210> 24 <211> 363 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Construct <400> 24 gaggtgcagc tggtggagtc tgggggaggc ttggtccagc ctggagggtc cctgagactc 60 tcctgtgcag cctctggctt caccagtacc gactactact ttagctgggt ccgccaggct 120 ccagggaagg ggctggagtg ggttggcttc atccggtcta agtcgaaggg ctacaccacc 180 gagtacagcg gcagcgtgaa gggcagattc accatctcaa gagatgattc aaagaactca 240 ctgtacctgc agatgaacag cctgaaaacc gaggacacgg ccgtgtatta ctgtgctaga 300 gagcccatca ccaccgaccc tcgggactac tggggccaag ggaccctggt caccgtctcc 360 tca 363 <210> 25 <211> 363 <212> DNA <213> Artificial Sequence Page 17 969450Seq.TXT <220> <223> Synthetic Construct <400> 25 gaggtgcagc tggtggagtc tgggggaggc ttggtccagc ctggagggtc cctgagactc 60 tcctgtgcag cctctggctt caccagtacc gactactact ttagctgggt ccgccaggct 120 ccagggaagg ggctggagtg ggttggcttc atccggtata agtcgaaggg ctacaccacc 180 gagtacagcg gcagcgtgaa gggcagattc accatctcaa gagatgattc aaagaactca 240 ctgtacctgc agatgaacag cctgaaaacc gaggacacgg ccgtgtatta ctgtgctaga 300 gagcccatca ccaccgaccc tcgggactac tggggccaag ggaccctggt caccgtctcc 360 tca 363 <210> 26 <211> 363 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Construct <400> 26 gaggtgcagc tggtggagtc tgggggaggc ttggtccagc ctggagggtc cctgagactc 60 tcctgtgcag cctctggctt caccagtacc gactactact ttagctgggt ccgccaggct 120 ccagggaagg ggctggagtg ggttggcttc atccggaaca agcggaaggg ctacaccacc 180 gagtacagcg gcagcgtgaa gggcagattc accatctcaa gagatgattc aaagaactca 240 ctgtacctgc agatgaacag cctgaaaacc gaggacacgg ccgtgtatta ctgtgctaga 300 gagcccatca ccaccgaccc tcgggactac tggggccaag ggaccctggt caccgtctcc 360 tca 363 <210> 27 <211> 363 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Construct <400> 27 gaggtgcagc tggtggagtc tgggggaggc ttggtccagc ctggagggtc cctgagactc 60 tcctgtgcag cctctggctt caccagtacc gactactact ttagctgggt ccgccaggct 120 ccagggaagg ggctggagtg ggttggcttc atccggcaca agtcgaaggg ctacaccacc 180 gagtacagcg gcagcgtgaa gggcagattc accatctcaa gagatgattc aaagaactca 240 ctgtacctgc agatgaacag cctgaaaacc gaggacacgg ccgtgtatta ctgtgctaga 300 gagcccatca ccaccgaccc tcgggactac tggggccaag ggaccctggt caccgtctcc 360 tca 363 <210> 28 Page 18 969450Seq.TXT <211> 336 <212> DNA <213> Artificial Sequence <220> <223> Synthetic Construct <400> 28 gacatcgtga tgacccagtc tccagactcc ctggctgtgt ctctgggcga gagggccacc 60 atcaactgca agagcagcca gagcctgttc aacagccgga cccggaagaa gtacctggcc 120 tggtaccagc agaaaccagg acagcctcct aagctgctca tttactgggc cagcaagaga 180 aagagcgggg tccctgaccg attcagtggc agcgggtctg ggacagattt cactctcacc 240 atcagcagcc tgcaggctga agatgtggca gtttattact gtaagcagag ccgttttctg 300 agagcctttg gccaagggac caagctggag atcaaa 336 <210> 29 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 29 Thr Glu Thr Ser Gln Val Ala Pro Ala 1 5 <210> 30 <211> 360 <212> PRT <213> Homo sapiens <400> 30 Met Glu Gly Ile Ser Ser Ile Pro Leu Pro Leu Leu Gln Ile Tyr Thr 1 5 10 15 Ser Asp Asn Tyr Thr Glu Glu Met Gly Ser Gly Asp Tyr Asp Ser Met 20 25 30 Lys Glu Pro Cys Phe Arg Glu Glu Asn Ala Asn Phe Asn Lys Ile Phe 35 40 45 Leu Pro Thr Ile Tyr Ser Ile Ile Phe Leu Thr Gly Ile Val Gly Asn 50 55 60 Gly Leu Val Ile Leu Val Met Gly Tyr Gln Lys Lys Leu Arg Ser Met 65 70 75 80 Thr Asp Lys Tyr Arg Leu His Leu Ser Val Ala Asp Leu Leu Phe Val 85 90 95 Ile Thr Leu Pro Phe Trp Ala Val Asp Ala Val Ala Asn Trp Tyr Phe 100 105 110 Page 19 969450Seq.TXT Gly Asn Phe Leu Cys Lys Ala Val His Val Ile Tyr Thr Val Asn Leu 115 120 125 Tyr Ser Ser Val Leu Ile Leu Ala Phe Ile Ser Leu Asp Arg Tyr Leu 130 135 140 Ala Ile Val His Ala Thr Asn Ser Gln Arg Pro Arg Lys Leu Leu Ala 145 150 155 160 Glu Lys Val Val Tyr Val Gly Val Trp Ile Pro Ala Leu Leu Leu Thr 165 170 175 Ile Pro Asp Phe Ile Phe Ala Asn Val Ser Glu Ala Asp Asp Arg Tyr 180 185 190 Ile Cys Asp Arg Phe Tyr Pro Asn Asp Leu Trp Val Val Val Phe Gln 195 200 205 Phe Gln His Ile Met Val Gly Leu Ile Leu Pro Gly Ile Val Ile Leu 210 215 220 Ser Cys Tyr Cys Ile Ile Ile Ser Lys Leu Ser His Ser Lys Gly His 225 230 235 240 Gln Lys Arg Lys Ala Leu Lys Thr Thr Val Ile Leu Ile Leu Ala Phe 245 250 255 Phe Ala Cys Trp Leu Pro Tyr Tyr Ile Gly Ile Ser Ile Asp Ser Phe 260 265 270 Ile Leu Leu Glu Ile Ile Lys Gln Gly Cys Glu Phe Glu Asn Thr Val 275 280 285 His Lys Trp Ile Ser Ile Thr Glu Ala Leu Ala Phe Phe His Cys Cys 290 295 300 Leu Asn Pro Ile Leu Tyr Ala Phe Leu Gly Ala Lys Phe Lys Thr Ser 305 310 315 320 Ala Gln His Ala Leu Thr Ser Val Ser Arg Gly Ser Ser Leu Lys Ile 325 330 335 Leu Ser Lys Gly Lys Arg Gly Gly His Ser Ser Val Ser Thr Glu Ser 340 345 350 Glu Ser Ser Ser Phe His Ser Ser 355 360 <210> 31 <211> 356 Page 20 969450Seq.TXT <212> PRT <213> Homo sapiens <400> 31 Met Ser Ile Pro Leu Pro Leu Leu Gln Ile Tyr Thr Ser Asp Asn Tyr 1 5 10 15 Thr Glu Glu Met Gly Ser Gly Asp Tyr Asp Ser Met Lys Glu Pro Cys 20 25 30 Phe Arg Glu Glu Asn Ala Asn Phe Asn Lys Ile Phe Leu Pro Thr Ile 35 40 45 Tyr Ser Ile Ile Phe Leu Thr Gly Ile Val Gly Asn Gly Leu Val Ile 50 55 60 Leu Val Met Gly Tyr Gln Lys Lys Leu Arg Ser Met Thr Asp Lys Tyr 65 70 75 80 Arg Leu His Leu Ser Val Ala Asp Leu Leu Phe Val Ile Thr Leu Pro 85 90 95 Phe Trp Ala Val Asp Ala Val Ala Asn Trp Tyr Phe Gly Asn Phe Leu 100 105 110 Cys Lys Ala Val His Val Ile Tyr Thr Val Asn Leu Tyr Ser Ser Val 115 120 125 Leu Ile Leu Ala Phe Ile Ser Leu Asp Arg Tyr Leu Ala Ile Val His 130 135 140 Ala Thr Asn Ser Gln Arg Pro Arg Lys Leu Leu Ala Glu Lys Val Val 145 150 155 160 Tyr Val Gly Val Trp Ile Pro Ala Leu Leu Leu Thr Ile Pro Asp Phe 165 170 175 Ile Phe Ala Asn Val Ser Glu Ala Asp Asp Arg Tyr Ile Cys Asp Arg 180 185 190 Phe Tyr Pro Asn Asp Leu Trp Val Val Val Phe Gln Phe Gln His Ile 195 200 205 Met Val Gly Leu Ile Leu Pro Gly Ile Val Ile Leu Ser Cys Tyr Cys 210 215 220 Ile Ile Ile Ser Lys Leu Ser His Ser Lys Gly His Gln Lys Arg Lys 225 230 235 240 Ala Leu Lys Thr Thr Val Ile Leu Ile Leu Ala Phe Phe Ala Cys Trp 245 250 255 Page 21 969450Seq.TXT Leu Pro Tyr Tyr Ile Gly Ile Ser Ile Asp Ser Phe Ile Leu Leu Glu 260 265 270 Ile Ile Lys Gln Gly Cys Glu Phe Glu Asn Thr Val His Lys Trp Ile 275 280 285 Ser Ile Thr Glu Ala Leu Ala Phe Phe His Cys Cys Leu Asn Pro Ile 290 295 300 Leu Tyr Ala Phe Leu Gly Ala Lys Phe Lys Thr Ser Ala Gln His Ala 305 310 315 320 Leu Thr Ser Val Ser Arg Gly Ser Ser Leu Lys Ile Leu Ser Lys Gly 325 330 335 Lys Arg Gly Gly His Ser Ser Val Ser Thr Glu Ser Glu Ser Ser Ser 340 345 350 Phe His Ser Ser 355 <210> 32 <211> 352 <212> PRT <213> Homo sapiens <400> 32 Met Glu Gly Ile Ser Ile Tyr Thr Ser Asp Asn Tyr Thr Glu Glu Met 1 5 10 15 Gly Ser Gly Asp Tyr Asp Ser Met Lys Glu Pro Cys Phe Arg Glu Glu 20 25 30 Asn Ala Asn Phe Asn Lys Ile Phe Leu Pro Thr Ile Tyr Ser Ile Ile 35 40 45 Phe Leu Thr Gly Ile Val Gly Asn Gly Leu Val Ile Leu Val Met Gly 50 55 60 Tyr Gln Lys Lys Leu Arg Ser Met Thr Asp Lys Tyr Arg Leu His Leu 65 70 75 80 Ser Val Ala Asp Leu Leu Phe Val Ile Thr Leu Pro Phe Trp Ala Val 85 90 95 Asp Ala Val Ala Asn Trp Tyr Phe Gly Asn Phe Leu Cys Lys Ala Val 100 105 110 His Val Ile Tyr Thr Val Asn Leu Tyr Ser Ser Val Leu Ile Leu Ala 115 120 125 Page 22 969450Seq.TXT Phe Ile Ser Leu Asp Arg Tyr Leu Ala Ile Val His Ala Thr Asn Ser 130 135 140 Gln Arg Pro Arg Lys Leu Leu Ala Glu Lys Val Val Tyr Val Gly Val 145 150 155 160 Trp Ile Pro Ala Leu Leu Leu Thr Ile Pro Asp Phe Ile Phe Ala Asn 165 170 175 Val Ser Glu Ala Asp Asp Arg Tyr Ile Cys Asp Arg Phe Tyr Pro Asn 180 185 190 Asp Leu Trp Val Val Val Phe Gln Phe Gln His Ile Met Val Gly Leu 195 200 205 Ile Leu Pro Gly Ile Val Ile Leu Ser Cys Tyr Cys Ile Ile Ile Ser 210 215 220 Lys Leu Ser His Ser Lys Gly His Gln Lys Arg Lys Ala Leu Lys Thr 225 230 235 240 Thr Val Ile Leu Ile Leu Ala Phe Phe Ala Cys Trp Leu Pro Tyr Tyr 245 250 255 Ile Gly Ile Ser Ile Asp Ser Phe Ile Leu Leu Glu Ile Ile Lys Gln 260 265 270 Gly Cys Glu Phe Glu Asn Thr Val His Lys Trp Ile Ser Ile Thr Glu 275 280 285 Ala Leu Ala Phe Phe His Cys Cys Leu Asn Pro Ile Leu Tyr Ala Phe 290 295 300 Leu Gly Ala Lys Phe Lys Thr Ser Ala Gln His Ala Leu Thr Ser Val 305 310 315 320 Ser Arg Gly Ser Ser Leu Lys Ile Leu Ser Lys Gly Lys Arg Gly Gly 325 330 335 His Ser Ser Val Ser Thr Glu Ser Glu Ser Ser Ser Phe His Ser Ser 340 345 350 <210> 33 <211> 67 <212> PRT <213> Homo sapiens <400> 33 Lys Pro Val Ser Leu Ser Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser 1 5 10 15 His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro Page 23 969450Seq.TXT 20 25 30 Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Asn Asn Asn Arg Gln Val 35 40 45 Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys Ala 50 55 60 Leu Asn Lys 65 Page 24